Logical Therapeutics Inc., which develops drugs for diseases associated with or caused by inflammation, raised $30 million in its Series B round to push its early stage pipeline through proof-of-concept trials, starting with a naproxen prodrug aimed at chronic pain.(BioWorld Today)